MX2021015776A - Composiciones farmaceuticas en la forma de gel que contienen xiloglucano y alcoholes para la liberacion controlada de principios activos. - Google Patents

Composiciones farmaceuticas en la forma de gel que contienen xiloglucano y alcoholes para la liberacion controlada de principios activos.

Info

Publication number
MX2021015776A
MX2021015776A MX2021015776A MX2021015776A MX2021015776A MX 2021015776 A MX2021015776 A MX 2021015776A MX 2021015776 A MX2021015776 A MX 2021015776A MX 2021015776 A MX2021015776 A MX 2021015776A MX 2021015776 A MX2021015776 A MX 2021015776A
Authority
MX
Mexico
Prior art keywords
controlled release
active ingredients
alcohols
pharmaceutical compositions
gel containing
Prior art date
Application number
MX2021015776A
Other languages
English (en)
Inventor
Clelia Dispenza
Giuseppe Claudio Viscomi
Paola Maffei
Cristiana Bruno
Mascia Federici
Maria Antonietta Sabatino
Original Assignee
Alfasigma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfasigma Spa filed Critical Alfasigma Spa
Publication of MX2021015776A publication Critical patent/MX2021015776A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a composiciones en gel que comprenden principios activos farmacéuticos; la composición comprende xiloglucano a una concentración entre 0.1% y 10.0% en peso total de la composición, junto con un alcohol a una concentración entre 5.0 y 50.0% en peso total de la composición; la invención también describe un procedimiento para la preparación de la composición y su uso en el tratamiento de patologías en donde es útil una liberación controlada del principio activo.
MX2021015776A 2019-06-21 2020-06-11 Composiciones farmaceuticas en la forma de gel que contienen xiloglucano y alcoholes para la liberacion controlada de principios activos. MX2021015776A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT201900009273 2019-06-21
PCT/EP2020/066181 WO2020254179A1 (en) 2019-06-21 2020-06-11 Pharmaceutical compositions in the form of gel containing xyloglucan and alcohols for the controlled release of active ingredients

Publications (1)

Publication Number Publication Date
MX2021015776A true MX2021015776A (es) 2022-01-31

Family

ID=68582095

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015776A MX2021015776A (es) 2019-06-21 2020-06-11 Composiciones farmaceuticas en la forma de gel que contienen xiloglucano y alcoholes para la liberacion controlada de principios activos.

Country Status (7)

Country Link
US (1) US20220241193A1 (es)
EP (1) EP3986378A1 (es)
JP (1) JP2022537460A (es)
CN (1) CN114096237A (es)
EA (1) EA202290122A1 (es)
MX (1) MX2021015776A (es)
WO (1) WO2020254179A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117281767B (zh) * 2022-10-18 2024-05-10 哈尔滨哈医集正医药科技开发有限公司 重组iii型胶原水凝胶组合物、制备方法及在医用皮肤和妇科修复凝胶、面膜上的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432449B1 (en) 1998-05-18 2002-08-13 Amgen Inc. Biodegradable sustained-release alginate gels
JP2002003398A (ja) 2000-04-17 2002-01-09 Ltt Institute Co Ltd 徐放製剤、その製造法及びワクチン
ITMI20031640A1 (it) * 2003-08-08 2005-02-09 Mipharm S P A Base per gel bioadesivi.
ITBO20050388A1 (it) 2005-06-06 2006-12-07 Alfa Wassermann Spa Formulazione mucoadesive utili in dispositivi medici in preparazioni farmaceutiche
KR100813224B1 (ko) 2007-08-24 2008-03-13 한양대학교 산학협력단 단백질 약물전달용 온도 가역성 코아세르베이트 조합 겔
CN102292354B (zh) * 2008-12-15 2014-04-02 科学与工业研究委员会 透明木葡聚糖/壳聚糖凝胶及其制备方法
ITBO20110461A1 (it) * 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
EP3173067B1 (en) 2015-11-16 2018-11-14 Istanbul Universitesi Rektorlugu Mucoadhesive buccal in situ gel formulation
JP6490134B2 (ja) 2017-04-05 2019-03-27 Ｄｓｐ五協フード＆ケミカル株式会社 キシログルカン含有ゲル状組成物

Also Published As

Publication number Publication date
WO2020254179A1 (en) 2020-12-24
EP3986378A1 (en) 2022-04-27
CN114096237A (zh) 2022-02-25
US20220241193A1 (en) 2022-08-04
JP2022537460A (ja) 2022-08-25
EA202290122A1 (ru) 2022-03-17

Similar Documents

Publication Publication Date Title
NI201900041A (es) 1, 2, 4-triazolonas 2, 4, 5-trisustituidas
MX2022014313A (es) Formulaciones para administracion oral de agentes activos con perfil de absorcion controlada.
HUP0303879A2 (hu) Zsíralkohol-etoxilátok alkalmazása penetrációt elősegítő szerként
JOP20220131A1 (ar) مركبات أمينو كينولون تحمل بدائل تستخدم كمثبطات لـ dgkalpha من أجل تنشيط المناعة
MX2011011459A (es) Formulacion de clavulanato para neuroproteccion y tratamiento de trastornos neurodegenerativos.
PH12016502100A1 (en) Liquid formulation comprising gm-csf neutralizing compound
CR20210686A (es) Análogos de 3–(5–metil–1,3–tiazol–2–il)–n–{(1r)–1–[2–(trifluor–metil)pirimidin–5–il]etil}benzamida
WO2015081904A3 (en) Polyurethaneurea solutions for compositions with active ingredients or fragrances
CR20220278A (es) Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y usos de los mismos
WO2021046315A3 (en) Inhibitors of encephalitic alphaviruses
MX2021015776A (es) Composiciones farmaceuticas en la forma de gel que contienen xiloglucano y alcoholes para la liberacion controlada de principios activos.
JP2020164548A (ja) メゾ−２，３−ブタンジオールを含有する組成物
KR20160046639A (ko) 메조-2,3-부탄디올을 방부제로서 함유하는 피부 외용제 조성물
IN2014MN00929A (es)
WO2010041908A3 (ko) 판두라틴 유도체 또는 보에센베르기아 판두라타 추출물의 신규한 용도
MX2016008546A (es) Reduccion de queloides utilizando alantoina topica.
ZA202200331B (en) Naltrexone formulation
WO2021161023A8 (en) Compounds useful in inhibiting ketohexokinase and methods of making and using the same
JP6971570B2 (ja) 花粉破裂抑制剤
MX2021015732A (es) Administracion intranasal de merotocina para mejorar la lactancia.
MX349868B (es) Composiciones de gel.
MX2021014425A (es) Composicion para el cuidado bucal.
CL2017002601A1 (es) Composición para formulación cosmética humectante de larga duración que comprende manteca de ucuuba (virola surinamensis), en una concentración de 1-5% del total de manteca y altas concentraciones de ácido mirístico así como su uso para la preparación de productos cosméticos (con efecto de tacto seco y pulverulento) con alta capacidad humectante y kit.
JP6940276B2 (ja) 花粉破裂抑制剤
MX2020011323A (es) Composicion farmaceutica para liberacion controlada de treprostinil.